Pragma Bio
Millbrae
About Pragma Bio
Pragma Bio is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $14.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2023)
- Website: pragmabio.com
- Phone: (650) 479-5539
Industries & Categories
Biotechnology, Predictive Analytics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/pragma-bio-71899 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.